Switch theme
Sign up to access all valuation multiples
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women’s Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
1923
11.6K+
LTM Revenue $2.5B
LTM EBITDA $928M
$4.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gedeon Richter has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $928M.
In the most recent fiscal year, Gedeon Richter achieved revenue of $2.4B and an EBITDA of $955M.
Gedeon Richter expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gedeon Richter valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Profit | $1.7B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $928M | XXX | $955M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 40% | XXX | XXX | XXX |
| EBIT | $791M | XXX | $728M | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $700M | XXX | $667M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gedeon Richter's stock price is HUF 10350 (or $29).
Gedeon Richter has current market cap of HUF 1.89T (or $5.3B), and EV of HUF 1.71T (or $4.8B).
See Gedeon Richter trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.8B | $5.3B | XXX | XXX | XXX | XXX | $3.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gedeon Richter has market cap of $5.3B and EV of $4.8B.
Gedeon Richter's trades at 2.0x EV/Revenue multiple, and 5.0x EV/EBITDA.
Equity research analysts estimate Gedeon Richter's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gedeon Richter has a P/E ratio of 7.5x.
See valuation multiples for Gedeon Richter and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 5.1x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBIT | 6.0x | XXX | 6.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 7.5x | XXX | 7.9x | XXX | XXX | XXX |
| EV/FCF | 8.9x | XXX | 7.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGedeon Richter's last 12 month revenue growth is 10%
Gedeon Richter's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Gedeon Richter's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gedeon Richter's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gedeon Richter and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gedeon Richter acquired XXX companies to date.
Last acquisition by Gedeon Richter was XXXXXXXX, XXXXX XXXXX XXXXXX . Gedeon Richter acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gedeon Richter founded? | Gedeon Richter was founded in 1923. |
| Where is Gedeon Richter headquartered? | Gedeon Richter is headquartered in Hungary. |
| How many employees does Gedeon Richter have? | As of today, Gedeon Richter has 11.6K+ employees. |
| Is Gedeon Richter publicy listed? | Yes, Gedeon Richter is a public company listed on BUD. |
| What is the stock symbol of Gedeon Richter? | Gedeon Richter trades under RICHTER ticker. |
| When did Gedeon Richter go public? | Gedeon Richter went public in 1994. |
| Who are competitors of Gedeon Richter? | Similar companies to Gedeon Richter include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Gedeon Richter? | Gedeon Richter's current market cap is $5.3B |
| What is the current revenue of Gedeon Richter? | Gedeon Richter's last 12 months revenue is $2.5B. |
| What is the current revenue growth of Gedeon Richter? | Gedeon Richter revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Gedeon Richter? | Current revenue multiple of Gedeon Richter is 1.9x. |
| Is Gedeon Richter profitable? | Yes, Gedeon Richter is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gedeon Richter? | Gedeon Richter's last 12 months EBITDA is $928M. |
| What is Gedeon Richter's EBITDA margin? | Gedeon Richter's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Gedeon Richter? | Current EBITDA multiple of Gedeon Richter is 5.1x. |
| What is the current FCF of Gedeon Richter? | Gedeon Richter's last 12 months FCF is $534M. |
| What is Gedeon Richter's FCF margin? | Gedeon Richter's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Gedeon Richter? | Current FCF multiple of Gedeon Richter is 8.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
